<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03010735</url>
  </required_header>
  <id_info>
    <org_study_id>CAUPCKD-02</org_study_id>
    <nct_id>NCT03010735</nct_id>
  </id_info>
  <brief_title>Effects of Probiotics on the Patients With End Stage Renal Disease (ESRD)</brief_title>
  <official_title>Effects of Bifidobacterium Animalis A6 on Metabolism of Uremic Toxin in Patients With End Stage Renal Disease (ESRD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Agricultural University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University Aerospace Centre Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Hospital of Chinese Armed Police Forces</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Anzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Biostats Technology Co. Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Heyiyuan Biotech Co. Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China Agricultural University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effects of oral administration of
      Bifidobacterium animalis A6 on the metabolism of uremic toxins, in the patients with End
      Stage Renal Disease (ESRD). One hundred and fifty hemodialysis patients are recruited, and a
      Double Blind Randomized Parallel Controlled Trial was performed.The microbiota-derived uremic
      toxin, such as indoxyl sulfate and p-cresol sulfate, are measured as Primary Outcome. The
      Fecal microbiome, fecal metabolites, blood metabolites, defecation, Gastrointestinal Symptoms
      The Kidney Disease Quality of Life and The Occurrence of Cardiovascular Event are also
      assessed.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Microbiota-derived uremic toxin</measure>
    <time_frame>6 months</time_frame>
    <description>follow up the patients at Month 0, 1, 2, 3, 6</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Fecal Microbiome</measure>
    <time_frame>6 months</time_frame>
    <description>follow up the patients at Month 0, 3, 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Fecal metabolites</measure>
    <time_frame>6 months</time_frame>
    <description>follow up the patients at Month 0, 3, 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Blood metabolites</measure>
    <time_frame>6 months</time_frame>
    <description>follow up the patients at Month 0, 3, 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Defecation questionnaire</measure>
    <time_frame>6 months</time_frame>
    <description>follow up the patients at Month 0, 1, 2, 3, 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal Symptoms</measure>
    <time_frame>6 months</time_frame>
    <description>follow up the patients at Month 0, 3, 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Kidney Disease Quality of Life</measure>
    <time_frame>6 months</time_frame>
    <description>follow up the patients at Month 0, 3, 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Occurrence of Cardiovascular Event</measure>
    <time_frame>6 month follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Kidney Failure, Chronic</condition>
  <arm_group>
    <arm_group_label>Probiotics</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patient take two chewing tablet per day, which contain 4.0E+10 CFU of Bifidobacterium animalis A6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The patient take two placebo chewing tablet per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bifidobacterium animalis A6</intervention_name>
    <description>Daily take 4.0E+10 CFU of Bifidobacterium animalis A6, 6 months</description>
    <arm_group_label>Probiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 18 years old

          -  Patients who diagnosed as ESRD with hemodialysis

          -  Fixed hemodialysis cycle (average 3 times a week)

          -  Agree to take the products to be studied during the study period, and no longer take
             other fermented dairy products (live lactic acid bacteria drinks, cheese, yogurt,
             probiotic products, etc.)

          -  Agree to sign the informed consent form

        Exclusion Criteria:

          -  Taking antibiotics or antifungal drugs within 30 days before the study

          -  Have serious allergic reaction to skim milk powder

          -  Researcher are not sure whether the subjects are willing or able to complete the study

          -  Subject participated in other research projects within two months before the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fazheng Ren, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>China Agricultural Universtiy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Chinese Armed Police Forces</name>
      <address>
        <city>Beijing</city>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University Aerospace Centre Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100049</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Vaziri ND, Wong J, Pahl M, Piceno YM, Yuan J, DeSantis TZ, Ni Z, Nguyen TH, Andersen GL. Chronic kidney disease alters intestinal microbial flora. Kidney Int. 2013 Feb;83(2):308-15. doi: 10.1038/ki.2012.345. Epub 2012 Sep 19.</citation>
    <PMID>22992469</PMID>
  </reference>
  <reference>
    <citation>Poesen R, Windey K, Neven E, Kuypers D, De Preter V, Augustijns P, D'Haese P, Evenepoel P, Verbeke K, Meijers B. The Influence of CKD on Colonic Microbial Metabolism. J Am Soc Nephrol. 2016 May;27(5):1389-99. doi: 10.1681/ASN.2015030279. Epub 2015 Sep 23.</citation>
    <PMID>26400570</PMID>
  </reference>
  <reference>
    <citation>Koppe L, Mafra D, Fouque D. Probiotics and chronic kidney disease. Kidney Int. 2015 Nov;88(5):958-66. doi: 10.1038/ki.2015.255. Epub 2015 Sep 16. Review.</citation>
    <PMID>26376131</PMID>
  </reference>
  <reference>
    <citation>Anders HJ, Andersen K, Stecher B. The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease. Kidney Int. 2013 Jun;83(6):1010-6. doi: 10.1038/ki.2012.440. Epub 2013 Jan 16. Review.</citation>
    <PMID>23325079</PMID>
  </reference>
  <reference>
    <citation>Ramezani A, Raj DS. The gut microbiome, kidney disease, and targeted interventions. J Am Soc Nephrol. 2014 Apr;25(4):657-70. doi: 10.1681/ASN.2013080905. Epub 2013 Nov 14. Review.</citation>
    <PMID>24231662</PMID>
  </reference>
  <reference>
    <citation>Poesen R, Claes K, Evenepoel P, de Loor H, Augustijns P, Kuypers D, Meijers B. Microbiota-Derived Phenylacetylglutamine Associates with Overall Mortality and Cardiovascular Disease in Patients with CKD. J Am Soc Nephrol. 2016 Nov;27(11):3479-3487. Epub 2016 May 26.</citation>
    <PMID>27230658</PMID>
  </reference>
  <reference>
    <citation>Meyer TW, Hostetter TH. Uremia. N Engl J Med. 2007 Sep 27;357(13):1316-25. Review.</citation>
    <PMID>17898101</PMID>
  </reference>
  <reference>
    <citation>Aronov PA, Luo FJ, Plummer NS, Quan Z, Holmes S, Hostetter TH, Meyer TW. Colonic contribution to uremic solutes. J Am Soc Nephrol. 2011 Sep;22(9):1769-76. doi: 10.1681/ASN.2010121220. Epub 2011 Jul 22.</citation>
    <PMID>21784895</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2016</study_first_submitted>
  <study_first_submitted_qc>January 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2017</study_first_posted>
  <last_update_submitted>January 4, 2017</last_update_submitted>
  <last_update_submitted_qc>January 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China Agricultural University</investigator_affiliation>
    <investigator_full_name>Fazheng Ren</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Kidney Failure, Chronic</keyword>
  <keyword>Probiotics</keyword>
  <keyword>Uremic toxins</keyword>
  <keyword>Gastrointestinal Microbiome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

